<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HETASTARCH</span><br/>(het'a-starch)<br/><span class="topboxtradename">HES, </span><span class="topboxtradename">Hespan, </span><span class="topboxtradename">Hydroxyethyl Starch, </span><span class="topboxtradename">Hextend<br/></span><b>Classifications:</b> <span class="classification">plasma volume expander</span><br/><b>Prototype: </b>Albumin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>6 g/100 mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic starch closely resembling human glycogen. Acts much like albumin and dextran but is claimed to be less likely to
         produce anaphylaxis or to interfere with cross matching or blood typing procedures. Causes no significant alterations in fibrinogen
         or clotting time but may prolong the PTT and PT. Not a substitute for blood or plasma.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Colloidal osmotic properties are approximately equal to those of human serum albumin. In hypovolemic patients, it increases
         arterial and venous pressures, heart rate, cardiac output, urine output, and colloidal osmotic pressure.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Early fluid replacement and plasma volume expansion when whole blood is not available or when there is no time for necessary
         cross matching. Used to expand plasma volume during cardiopulmonary bypass and in adjunctive treatment of shock caused by
         hemorrhage, burns, surgery, sepsis, or other trauma. Also used as sedimenting agent in preparation of granulocytes by leukopheresis.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>As a priming fluid in pump oxygenators for perfusion during extracorporeal circulation and as a cryoprotective agent for long-term
         storage of whole blood.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe bleeding disorders, CHF, renal failure with oliguria and anuria, treatment of shock not accompanied by hypovolemia,
         pregnancy (category C). Safe use in children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic or renal insufficiency, pulmonary edema in the very young or older adults, patients on sodium restriction.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Plasma Volume Expansion</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 5001000 mL at a maximum rate of 20 mL/kg/h (max: 1500 mL/d)<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 10 mL/kg/dose (max: 20 mL/kg/24 h)<br/><br/><span class="indicationtitle">Leukapheresis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 250750 mL infused at a constant fixed ratio of 8:1 to venous whole blood<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Use undiluted as prepared by manufacturer.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Specific flow rate is prescribed by physician. Rate may be as high as 20 mL/kg/h in acute hemorrhagic shock. Rate is usually
                  reduced in patients with burns or septic shock.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store at room temperature; avoid extremes of heat or cold. </li>
<li>Discard partially used bags.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> CV:</span> Peripheral edema, <span class="speceff-life">circulatory overload, heart failure</span>. <span class="typehead">Hematologic:</span> With large volumes, prolongation of PT, PTT, clotting time, and bleeding time; decreased Hct, Hgb, platelets, calcium, and
      fibrinogen; dilution of plasma proteins, hyperbilirubinemia, increased sedimentation rate. <span class="typehead"> Body as a Whole:</span> Pruritus, <span class="speceff-life">anaphylactoid reactions</span> (periorbital edema, urticaria, wheezing), vomiting, mild fever, chills, influenza-like symptoms, headache, muscle pains,
      submaxillary and parotid glandular swelling. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> 2436 h. <span class="typehead">Distribution:</span> Remains in intravascular space. <span class="typehead">Metabolism:</span> Metabolized in reticuloendothelial system. <span class="typehead">Elimination:</span> Excreted in urine with some biliary excretion. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of hypersensitivity reaction (see Appendix F).</li>
<li>Measure and record I&amp;O. Report oliguria or significant changes in I&amp;O ratio.</li>
<li>Monitor BP and vital signs and observe patient for unusual bruising or bleeding.</li>
<li>Lab tests: Monitor WBC count with differential, platelet count, and PT &amp; PTT during leukapheresis.</li>
<li>Observe for signs of circulatory overload (see Appendix F).</li>
<li>Check laboratory reports of Hct values. Notify physician if there is an appreciable drop in Hct or if value approaches 30%
            by volume. Hct should not be allowed to drop below 30%.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician for any of the following: Difficulty breathing, nausea, chills, headache, itching.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>